Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Johannes Schüller"'
Autor:
Claus Henning Köhne, Piercarlo Saletti, Werner Scheithauer, Johannes Schüller, Thomas Ruhstaller, Bengt Glimelius, Karin Tàmas, Dieter Koeberle, György Bodoky, Gabriela Kornek, Emilio Bajetta, Richard Herrmann, W. Mingrone, Daniel Dietrich, J. Bauer, Salomon M. Stemmer, Arie Figer, Jürg Bernhard, D Gerber, Bernhard C. Pestalozzi
Publikováno v:
Journal of Clinical Oncology. 26:3695-3701
Purpose To compare clinical benefit response (CBR) and quality of life (QOL) in patients receiving gemcitabine (Gem) plus capecitabine (Cap) versus single-agent Gem for advanced/metastatic pancreatic cancer. Patients and Methods Patients were randoml
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::476bac385ab405035fd51f8f4c15dff1
https://doi.org/10.1200/jco.2007.15.6240
https://doi.org/10.1200/jco.2007.15.6240
Autor:
Thomas Ruhstaller, Bernhard C. Pestalozzi, Claus-Henning Köhne, Daniel Dietrich, Werner Scheithauer, Richard Herrmann, J. Bauer, Bengt Glimelius, Piercarlo Saletti, Johannes Schüller, Salomon M. Stemmer, Karin Tàmas, Gabriela Kornek, W. Mingrone, Emilio Bajetta, Dieter Koeberle, György Bodoky, Arie Figer, Jürg Bernhard, Susanne Cina
Publikováno v:
Journal of Clinical Oncology. 25:2212-2217
Purpose This phase III trial compared the efficacy and safety of gemcitabine (Gem) plus capecitabine (GemCap) versus single-agent Gem in advanced/metastatic pancreatic cancer. Patients and Methods Patients were randomly assigned to receive GemCap (or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d70c078a6bdf78c2ba9d7664cf3c5ef7
https://doi.org/10.1200/jco.2006.09.0886
https://doi.org/10.1200/jco.2006.09.0886
Autor:
A. Wong, Hendrik Kröning, Borut Stabuc, Jan Fagerberg, M. Pawlicki, Duncan I. Jodrell, Jean-François Seitz, Chris Twelves, Fares Husseini, Markus Abt, Vassilis Georgoulias, Jerzy Zaluski, Jerzy Tujakowski, Joseph McKendrick, P. Koralewski, Jim Cassidy, Guy van Hazel, Norbert Marschner, Jean A. Maroun, Alfredo Carrato, Johannes Schüller, Andrés Cervantes, Riccardo Rosso, M. Nowacki, Howard A. Burris, Werner Scheithauer
Publikováno v:
New England Journal of Medicine. 352:2696-2704
BACKGROUND Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bd28ec30a1c52a3aaff97e83c8d4ad4
https://doi.org/10.1056/nejmoa043116
https://doi.org/10.1056/nejmoa043116
Autor:
Erhard Weidekamm, Masaru Kuranami, Yasutsuna Sasaki, John Bridgewater, Cahit Yorulmaz, Susan Grange, Helen Lucraft, Jayne Monkhouse, Bruno Reigner, Toru Watanabe, Christopher Poole, Mitsunori Kimura, Toshiaki Saeki, J. J. McAleer, Johannes Schüller
Publikováno v:
Cancer Chemotherapy and Pharmacology. 52:193-201
Capecitabine (Xeloda) is a novel, oral fluoropyrimidine carbamate rationally designed to generate 5-fluorouracil (5-FU) preferentially in tumor tissue via a three-step enzymatic cascade.The objective of this study was to compare the pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b84d52f486ae3eb0aa793801f7123611
https://doi.org/10.1007/s00280-003-0642-8
https://doi.org/10.1007/s00280-003-0642-8
Autor:
Heinz Huber, Peter Günczler, Amos M. Cohen, Heinz Ludwig, W. F. Jungi, Sándor Eckhardt, H. L. Seewann, Johannes Schüller, David Nachbaur, Elke Fritz, Hans-Jörg Senn, Franco Cavalli, Michael Micksche
Publikováno v:
European Journal of Cancer and Clinical Oncology. 27:S40-S45
The present trial was designed to evaluate whether interferon (IFN) combined with standard induction chemotherapy and/or interferon remission maintenance treatment improve treatment results in patients with multiple myeloma. Up to now 89 patients hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f440aeffc1fe1d820f658830127a6cb
https://doi.org/10.1016/0277-5379(91)90570-4
https://doi.org/10.1016/0277-5379(91)90570-4
Treatment of patients with advanced colorectal cancer with cisplatin, 5-fluorouracil, and leucovorin
Autor:
Arthur P. Marczell, F. Ernst, Johannes Schüller, Ch. Sebesta, Harald R. Rosen, M. Karall, E. Hentschel, G. V. Kornek, R. Schiessel, D. Depisch, Werner Scheithauer
Publikováno v:
Cancer. 67:1294-1298
Based on in vitro studies that have demonstrated synergy between 5-fluorouracil (5-FU), leucovorin (LV), and cisplatin (CDDP) against human colon cancer cell lines, a clinical trial was initiated to determine the effects of this combination in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b3ee449d7c24d6b50df962a73971ad4
https://doi.org/10.1002/1097-0142(19910301)67:5<1294::aid-cncr2820670504>3.0.co
https://doi.org/10.1002/1097-0142(19910301)67:5<1294::aid-cncr2820670504>3.0.co
Autor:
Johannes Schüller, Peter Preis, D. Depisch, Berthold Greifenberg, Julius Wiegele, Heinz Ludwig, Werner Scheithauer, Christoph Zielinsky, H. Samonigg, Heinz Stöger, Hubert Hausmaninger, Werner Seidl, K. Haider
Publikováno v:
Investigational New Drugs. 8:207-210
In a phase II study, 77 patients with metastatic breast cancer were treated with pirarubicin, 70 mg/m2 iv every 3 weeks. Most of them had received prior hormonal (n = 39) and/or chemotherapeutic drug treatment for advanced disease, including anthracy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff7572874e40b282a8779e795e68077f
https://doi.org/10.1007/bf00177262
https://doi.org/10.1007/bf00177262
Publikováno v:
Scientia Pharmaceutica
Volume 69
Issue 4
Pages 289-297
Volume 69
Issue 4
Pages 289-297
The cytoprotective agent amifostine (AMI) is capable to protect healthy cells (contrary to tumor cells) due to higher activity of alkaline phosphatase at the membrane site of normal cells. In seven clinical trials the influence of AMI on the pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ef092cee5ef4726fc35b5d1b552ce09
Publikováno v:
Scientia pharmaceutica. 69(4)
The cytoprotective agent amifostine (AMI) is capable to protect healthy cells (contrary to tumor cells) due to higher activity of alkaline phosphatase at the membrane site of normal cells. In seven clinical trials the influence of AMI on the pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::79d14c9f27efd821fbb7fab492b61d85
https://pubmed.ncbi.nlm.nih.gov/28841172
https://pubmed.ncbi.nlm.nih.gov/28841172
Autor:
O. Michielin, Silke Gillessen, Richard Cathomas, Johannes Schüller, B. Seifert, Marc Schläppi, R. von Moos, Simone M. Goldinger, Adrian F. Ochsenbein, Reinhard Dummer
Publikováno v:
European Journal of Cancer Supplements. 7:13-14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::752c66bb4c393fa7e01019185a8c436d
https://doi.org/10.1016/s1359-6349(09)72059-2
https://doi.org/10.1016/s1359-6349(09)72059-2